| Name | Title | Contact Details |
|---|---|---|
Spencer Clark |
SVP and General Counsel | Profile |
Roxanne Womack |
SVP, Chief Compliance Officer | Profile |
Spencer Clark |
VP and Senior Legal Counsel | Profile |
Kelly Whelan |
VP and Senior Legal Counsel, American and Eastern Groups | Profile |
The Curry Rockefeller Group is a Tarrytown, NY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Spire Orthopedic Partners is a growing national partnership of orthopedic practices that provides the support, capital and operational resources physicians need to grow thriving practices for the future. As a management services organization, Spire provides the infrastructure for administrative operations that allows practices to operate at their highest level, so doctors can focus their efforts on what matters most – patient care. Rooted in the 100-plus-year legacy of its founding partners, the network spans the Northeast with 50 physicians, 450 employees and 10 locations from Connecticut to New York.
Vertiflex is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in San Clemente, CA. To find more information about Vertiflex, please visit www.vertiflex.net
https://t.co/QHy4u1rf0W is a next-gen mental wellness company that believes in the power of psychedelics to catalyze lasting change.
MolecularMD founders Brian Druker (lead clinical investigator for Gleevec, the first molecularly-targeted anticancer agent) and Sheridan G. Snyder (entrepreneur, founder of Genzyme and Upstate Biotechnology) came together with the mission of providing precise, standardized molecular testing for new oncology drugs. The company’s initial accomplishment was in developing and implementing the only standardized assay for quantification of BCR-ABL expression levels, which proved critical to pharmaceutical sponsors in satisfying regulators for approval of the second-generation ABL kinase inhibitors nilotinib (Tasigna, Novartis) and dasatinib (Sprycel, BMS). With that foundational success in supporting pivotal international studies with centralized, high-quality diagnostic services, MolecularMD has become a preferred provider of molecular diagnostics products and services to pharmaceutical and biotech drug developers. Capabilities range from specialty molecular testing services performed in MolecularMD’s centralized CLIA-certified and CAP-accredited laboratory, to development of FDA approved companion diagnostics to support new drug registrations.